EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA has authorized Avtozma, a tocilizumab biosimilar, for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, and COVID-19. The mark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• AVTOZMA (TOCILIZUMAB)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;COVID-19 virus infection. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 11/12/2025